about
Drug delivery and nanoparticles:applications and hazardsMolecular determinants of blood-brain barrier permeationXenobiotic pulmonary exposure and systemic cardiovascular response via neurological linksThe effect of ventilation, age, and asthmatic condition on ultrafine particle deposition in childrenProgress and problems in the application of focused ultrasound for blood-brain barrier disruption.Risks from accidental exposures to engineered nanoparticles and neurological health effects: a critical review.Structural modifications of (1S,3S)-3-amino-4-difluoromethylenecyclopentanecarboxylic acid, a potent irreversible inhibitor of GABA aminotransferaseFrom the liver to the brain across the blood-brain barrier.Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrierBlood-brain barrier transport of therapeutics via receptor-mediationFabrication of pRNA nanoparticles to deliver therapeutic RNAs and bioactive compounds into tumor cells.Stable RNA nanoparticles as potential new generation drugs for cancer therapy.Potential of polymeric nanoparticles in AIDS treatment and prevention.Lipid complexes with cationic peptides and OAKs; their role in antimicrobial action and in the delivery of antimicrobial agents.Magnetic nanoparticles: an update of application for drug delivery and possible toxic effects.Implantable and transdermal polymeric drug delivery technologies for the treatment of central nervous system disorders.Effects of radiofrequency radiation exposure on blood-brain barrier permeability in male and female rats."Clicked" sugar-curcumin conjugate: modulator of amyloid-β and tau peptide aggregation at ultralow concentrations.Pharmacokinetics and efficiency of brain targeting of ginsenosides Rg1 and Rb1 given as Nao-Qing microemulsion.Toxicity and bio-accumulation of inhaled cerium oxide nanoparticles in CD1 mice.Blood-brain barrier disruption by continuous-wave radio frequency radiation.Micro-/nano-sized delivery systems of ginsenosides for improved systemic bioavailability.Patented therapeutic RNAi strategies for neurodegenerative diseases of the CNS
P2860
Q24655744-44B02255-9C40-4F20-A3AA-1EB7825128F0Q26797482-7CE44211-EACB-4969-8EFF-F53A962471BBQ28082446-8B431E37-10A0-43C1-9CC7-7B22FC66FCDFQ28386644-83C782EB-0FD5-4D0B-8629-74590595F405Q30487878-66B5BC1D-CFD9-4B6E-83FD-AD3E45924636Q34468073-76AC057F-DCB6-42DB-8DC4-1E2650D549BFQ35754132-3D78E8D9-0892-4B2D-8AD9-15C0F581847FQ35778166-0F0AEC33-B767-419A-8F34-12202D057DAEQ36637219-D5EF287B-FBD8-4072-B014-E2471649494FQ36874295-D7A1C338-DD0C-480A-BB63-823FEDD88FA5Q37442480-F18831C0-4D8C-41C4-91C5-507635E4903EQ37640468-2A8CDA3B-FA67-45C8-A630-6031305305C0Q37818325-3269CF6E-1B21-446C-A38D-0B42FCE6A586Q37875766-1292E9EC-CDDD-4DF3-A92D-A5F881B1E48BQ37955034-94D7B61C-8A7C-4623-A16D-B8CDEB9B83E3Q38857113-69E4B2B5-E4E6-4DCF-9545-2F1C36E2256BQ39690970-CDE4E719-FBFF-4AE5-B86E-26A54B8E0DCEQ41992508-93FC611B-031C-4E4E-A4ED-8EF3A1C14757Q43598727-32E4834B-6DE6-4131-AD56-CE6A89965BACQ45213989-AF266DCC-C50E-4C32-BF91-0613C9CB803DQ48439831-6DEEA157-EAC0-4C67-BEAB-7B5C47CF84BCQ55431488-81417A04-6BAC-4A9D-95E6-2391036ABC60Q57675694-A3F17EDF-8C97-417B-B405-72F00C4EC4B6
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The blood-brain barrier and brain drug delivery.
@ast
The blood-brain barrier and brain drug delivery.
@en
type
label
The blood-brain barrier and brain drug delivery.
@ast
The blood-brain barrier and brain drug delivery.
@en
prefLabel
The blood-brain barrier and brain drug delivery.
@ast
The blood-brain barrier and brain drug delivery.
@en
P2093
P356
P1476
The blood-brain barrier and brain drug delivery.
@en
P2093
P304
P356
10.1166/JNN.2006.441
P407
P577
2006-09-01T00:00:00Z